Status:
COMPLETED
GIOTRIF rPMS in Korean Patients With NSCLC
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Carcinoma, Non-Small-Cell Lung
Eligibility:
All Genders
19-110 years
Brief Summary
To monitor the safety profile and efficacy of GIOTRIF® (afatinib dimaleate, q.d) in Korean patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients who have been started on GIOTRIF® in accordance with the approved label in Korea
- Age = 19 years at enrolment
- Patients who have signed on the data release consent form
- Exclusion criteria:
- Known hypersensitivity to afatinib or any of its excipients
- Patients with rare hereditary conditions of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption
- Patients for whom GIOTRIF® is contraindicated according to the local label
Exclusion
Key Trial Info
Start Date :
October 31 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2019
Estimated Enrollment :
1272 Patients enrolled
Trial Details
Trial ID
NCT02285361
Start Date
October 31 2014
End Date
December 31 2019
Last Update
February 24 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Multiple Locations, South Korea